SOCS1 Haploinsufficiency

Mendelian MONDO:0800130 Pathograph 13 Show in embeddings browser

Autoinflammatory syndrome with immunodeficiency (OMIM 619375) is an autosomal dominant inborn error of immunity caused by heterozygous loss-of-function variants in SOCS1, with incomplete penetrance. SOCS1 is the negative-feedback brake on JAK-STAT signalling. Losing one functional copy does not remove a cytokine or a receptor - it removes the off-switch, so cells respond excessively to cytokines that are present at ordinary levels. Patient lymphocytes show increased STAT activation to interferon-gamma, IL-2 and IL-4, and the excess is reversed in vitro by a JAK1/JAK2 inhibitor. The resulting disease is simultaneously autoimmune and immunodeficient, which is the feature that makes it worth curating as its own entity rather than as an autoimmunity syndrome. The reported spectrum runs from autoimmune cytopenias, thyroiditis, nephritis and lupus-like disease through hypogammaglobulinaemia and recurrent infection to malignancy - all from one gene, in a dosage-sensitive pathway whose job is restraint rather than activation.

Ask OpenScientist

Ask a research question about SOCS1 Haploinsufficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
11
Pathophys.
8
Phenotypes
3
Gaps
13
Pathograph
1
Genes
2
Medical Actions
2
Differentials
3
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant HP:0000006
Autosomal dominant with incomplete penetrance. Disease arises from haploinsufficiency - one functional allele does not supply enough SOCS1 to restrain JAK-STAT signalling - rather than from a dominant-negative effect.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"by whole-exome/genome sequencing we identify heterozygous, autosomal-dominant, germline loss-of-function mutations in the SOCS1 gene in ten patients from five unrelated families with early onset autoimmune manifestations"
Establishes the inheritance pattern, the variant class, and the size of the founding cohort.
?

Discussions and Knowledge Gaps

3
Is the Th17 compartment reduced in SOCS1 haploinsufficiency, and if so is that the route to the infection-susceptibility arm?
KNOWLEDGE GAP gap_th17_compartment_disagreement
Attached to
pathophysiology#Reduced STAT3 Phosphorylation pathophysiology#Th17 Compartment Reduction
The two patient series in this entry disagree, and the disagreement is curated rather than adjudicated because neither result is obviously the weaker one. Michniacki and colleagues report reduced STAT3 phosphorylation with a concurrent reduction of Th17 cells; Hadjadj and colleagues, in the founding ten-patient cohort, explicitly looked and did not observe an imbalance in Th1, Th2, Th17 or T follicular helper cells. The cohorts differ in size, assay and whether CRISPR-edited primary T cells were used alongside patient cells, any of which could account for it. This is not a bookkeeping dispute: a reduced Th17 compartment is the most concrete available candidate for the intermediates on the INDIRECT_UNKNOWN_INTERMEDIATES edge into the immunodeficiency arm, so whether it is real determines whether that edge can be specified. It also bears on therapy, since IL-17 blockade has been used successfully in at least one patient - which is difficult to reconcile with Th17 already being depleted.
Proposed experiments
Re-measure the Th17 compartment across both cohorts with a harmonised assay
exp_socs1_th17_harmonized_assay
Apply one intracellular-cytokine and STAT3-phosphorylation protocol to patient samples from both series, stratified by treatment status at sampling, and pair it with IL-17 functional readouts. If Th17 reduction replicates only in patients already on immunosuppression it is iatrogenic rather than mechanistic; if it replicates in untreated patients, the immunodeficiency edge can be specified and the IL-17-blockade response needs a different explanation.
How does a single defect that makes immune cells hypersensitive to cytokines produce immunodeficiency and hypogammaglobulinaemia alongside autoimmunity?
KNOWLEDGE GAP gap_autoimmunity_and_immunodeficiency_from_one_defect
Attached to
pathophysiology#Humoral Immunodeficiency and Infection Susceptibility
The autoimmune arm follows straightforwardly from lymphocyte hyperactivity. The immunodeficient arm does not: a system that responds too strongly ought not to respond too little. Candidate explanations include activation-induced exhaustion or death of chronically stimulated lymphocytes, disruption of B-cell maturation by excess interferon signalling, or the immunodeficiency being partly iatrogenic in patients treated with immunosuppression for their autoimmunity - a confound that is hard to exclude in a disease whose autoimmune manifestations usually present first. Distinguishing these matters for whether JAK inhibition would be expected to improve or worsen the infection susceptibility.
Proposed experiments
B-cell maturation phenotyping in treatment-naive SOCS1 haploinsufficient patients
exp_socs1_bcell_maturation_untreated
Characterise B-cell subsets, class-switching and immunoglobulin levels in patients before any immunosuppressive therapy, and again on JAK inhibition. If hypogammaglobulinaemia is present pre-treatment it is intrinsic to the disease; if it emerges only after immunosuppression, the immunodeficient arm is substantially iatrogenic and the entry's causal chain should be revised.
Why did blocking just two cytokine axes control disease in a patient whose cells were hyper-responsive to many?
KNOWLEDGE GAP gap_broad_defect_narrow_therapy
Attached to
pathophysiology#Cytokine Hypersensitivity with Increased STAT Activation
Patient cells show excess STAT activation to interferon-gamma, IL-2, IL-4 and more, yet one patient's clinical disease responded markedly to IL4Rα and IL-17 blockade alone. Either the laboratory hyper-responsiveness overstates which axes actually drive tissue pathology, or the driving axes differ between patients and this patient's happened to be those two. The distinction is directly actionable: the first would justify trying targeted biologics before broad JAK inhibition, the second would mean the choice has to be made per patient from the phenotype. With single-patient evidence, neither is established.
Proposed experiments
Map per-patient cytokine hyper-responsiveness against clinical manifestations
exp_socs1_axis_to_phenotype_mapping
Across a SOCS1 cohort, measure STAT activation per cytokine axis and score it against each patient's dominant clinical features. A consistent axis-to-phenotype mapping would support choosing targeted blockade rationally rather than defaulting to JAK inhibition.
⚙

Pathophysiology

11
Heterozygous SOCS1 Loss of Function
Germline heterozygous loss-of-function variants in SOCS1. Reported alleles include frameshifts producing complete loss of protein expression from the affected allele; one such variant, c.202_203delAC (p.Thr68fsAla*49), was shown to abolish the protein's ability to inhibit JAK-STAT signalling when expressed in vitro.
Downstream
Loss of JAK-STAT Negative Feedback
Loss of SOCS-Box E3 Ligase Function The same halved gene relieves both of SOCS1's activities. The SH2 domain stops inhibiting JAK and the SOCS-box stops assembling its E3 ligase; neither arm is downstream of the other.
Show evidence (1 reference)
PMID:38157076 SUPPORT In Vitro
"The variant, c.202_203delAC, generates a frameshift in SOCS1, p.Thr68fsAla*49, which leads to complete loss of protein expression."
Documents a specific frameshift allele and confirms it is a true null.
Loss of JAK-STAT Negative Feedback
SOCS1 is an intracellular inhibitor of the JAK-STAT pathway - a brake, not a signal. Haploinsufficiency therefore does not alter what cytokines are present; it alters how strongly cells answer them. The mutant protein fails to perform the inhibition that wild-type SOCS1 does.
negative regulation of cytokine-mediated signaling pathway GO:0001960 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased negative regulation of cytokine-mediated signaling pathway (GO:0001960). GO:0001960 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Cytokine Hypersensitivity with Increased STAT Activation
Reduced STAT3 Phosphorylation The same loss of feedback that raises STAT1 lowers STAT3. Both are downstream of the brake rather than of each other, which is why they are drawn as sibling arms.
Show evidence (2 references)
PMID:33087723 SUPPORT Human Clinical
"The intracellular protein SOCS1 is known to downregulate cytokine signaling by inhibiting the JAK-STAT pathway."
Establishes SOCS1's normal function as the brake whose loss defines this disease.
PMID:38157076 SUPPORT In Vitro
"Unlike WT SOCS1, Thr68fs SOCS1 fails to inhibit JAK-STAT signaling when expressed in vitro."
Direct functional demonstration that the variant protein cannot inhibit the pathway.
Cytokine Hypersensitivity with Increased STAT Activation
The central defect, and the one that is directly measurable in patients. Patient lymphocytes show increased STAT activation in response to interferon-gamma, IL-2 and IL-4 - three cytokines with different receptors and different downstream programmes, which is why the disease is pleiotropic rather than confined to one axis. Monocyte subpopulations are redistributed and hyper-responsive across multiple cytokine pathways. The hypersensitivity is not uniform across STATs, and that matters. STAT1 phosphorylation is enhanced to a degree comparable with STAT1 gain-of-function disease, but STAT3 phosphorylation is REDUCED, with a concurrent fall in Th17 cells. So losing the brake does not simply turn everything up: the disease overlaps clinically with both STAT1 gain-of-function and STAT3 loss-of-function, and a description of it as global cytokine hyper-responsiveness is incomplete.
lymphocyte CL:0000542 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves lymphocyte (CL:0000542). CL:0000542 is a cell type from the Cell Ontology.
cell surface receptor signaling pathway via JAK-STAT GO:0007259 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell surface receptor signaling pathway via JAK-STAT (GO:0007259). GO:0007259 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Lymphocyte Hyperactivity
Show evidence (4 references)
PMID:33087723 SUPPORT Human Clinical
"patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-γ, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib"
Demonstrates the hypersensitivity across three distinct cytokines and establishes its pharmacological reversibility, which is the basis of the treatment link below.
PMID:38157076 SUPPORT Human Clinical
"The peripheral immune signature from this patient was marked by a redistribution of monocyte sub-populations and hyper-responsiveness to multiple cytokines."
Extends the hypersensitivity beyond lymphocytes to the monocyte compartment.
PMID:34421895 SUPPORT Human Clinical
"STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function mutations, and STAT3 phosphorylation is similarly reduced with concurrent reduction of Th17 cells."
Curated as PARTIAL against the node's framing rather than as plain support: it establishes the hypersensitivity for STAT1 while showing the opposite for STAT3, so it qualifies the node as much as it supports it.
+ 1 more reference
Lymphocyte Hyperactivity
Cytokine hypersensitivity translates into a broad set of immune abnormalities consistent with lymphocytes that are too easily activated. This is the node from which the disease's two apparently opposite arms both descend.
Downstream
Defective Regulatory T Cell Compartment
Impaired B Cell Maturation
Loss of Self-Tolerance and Autoimmunity
Humoral Immunodeficiency and Infection Susceptibility
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"This effect is associated with a series of in vitro and in vivo immune abnormalities consistent with lymphocyte hyperactivity."
Establishes lymphocyte hyperactivity as the consequence of cytokine hypersensitivity.
Defective Regulatory T Cell Compartment
The cellular mechanism for the tolerance failure, which the hyperactivity node cannot supply on its own. Patients have a reduced frequency of CD4+CD25+FOXP3+ Tregs, lower expression of FOXP3 and HELIOS, and moderately but significantly reduced suppressive activity. The reduction is not an artefact of memory CD4 expansion. This matters directionally: a disease of excess signalling also removes the cells whose job is to restrain it, so the two arms compound rather than merely coexist.
CD4+CD25+FOXP3+ regulatory T cell CL:0000815 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves decreased CD4+CD25+FOXP3+ regulatory T cell, annotated with regulatory T cell (CL:0000815). CL:0000815 is a cell type from the Cell Ontology. ↓ DECREASED
Downstream
Loss of Self-Tolerance and Autoimmunity
Show evidence (2 references)
PMID:33087723 SUPPORT Human Clinical
"This reduction in T regs frequency was not due to the expansion of memory CD4 T cells"
Establishes the Treg frequency reduction in patients and excludes the trivial explanation that it reflects expansion of another CD4 compartment.
PMID:34421895 SUPPORT Human Clinical
"Additionally regulatory T cells are reduced in most SOCS1"
Independent corroboration in a second patient series, which is why this is curated as a mechanism node rather than a single-cohort observation.
Reduced STAT3 Phosphorylation
The finding that breaks the uniform-hypersensitivity framing. Losing a JAK-STAT brake does not raise every STAT equally: STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function mutations, but STAT3 phosphorylation is reduced. A brake whose removal lowers one of its own substrates is not behaving as a simple brake, which is why this arm is modelled separately from the hypersensitivity node rather than as part of it.
STAT3 tyrosine phosphorylation GO:0007260 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased STAT3 tyrosine phosphorylation, annotated with tyrosine phosphorylation of STAT protein (GO:0007260). GO:0007260 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Th17 Compartment Reduction
Show evidence (1 reference)
PMID:34421895 SUPPORT Human Clinical
"STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function mutations, and STAT3 phosphorylation is similarly reduced with concurrent reduction of Th17 cells."
States both halves of the asymmetry, which is what makes "cytokine hypersensitivity" an incomplete description of the molecular phenotype.
Th17 Compartment Reduction
The cellular consequence of the reduced STAT3 signal, STAT3 being required for Th17 differentiation. A reduced Th17 compartment is a plausible route to the infection-susceptibility arm whose intermediates the entry otherwise leaves unknown, so the edge below is curated as a candidate explanation rather than an established one: the two cohorts disagree about Th17, which is recorded as a discussion rather than resolved here.
T-helper 17 cell CL:0000899 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves decreased T-helper 17 cell (CL:0000899). CL:0000899 is a cell type from the Cell Ontology. ↓ DECREASED
T-helper 17 cell differentiation GO:0072539 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased T-helper 17 cell differentiation (GO:0072539). GO:0072539 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Humoral Immunodeficiency and Infection Susceptibility Curated as a candidate route, not an established one. Th17 cells defend mucosal surfaces against extracellular bacteria and fungi, so their loss is a mechanistically coherent contributor to the infection arm - but the Th17 finding itself is disputed between the two cohorts, so the edge is left indirect rather than asserted as the explanation.
Show evidence (1 reference)
PMID:34421895 SUPPORT Human Clinical
"STAT3 phosphorylation is similarly reduced with concurrent reduction of Th17 cells."
Ties the Th17 fall to the reduced STAT3 signal in the same patients.
Loss of SOCS-Box E3 Ligase Function
The second of SOCS1's two domains, and the arm the entry previously omitted entirely - modelling a two-domain protein as a one-domain brake. Beyond the SH2-mediated JAK inhibition, SOCS1 uses its C-terminal SOCS-box to assemble a Cullin5-Rbx2 E3 ligase that ubiquitinates substrates for degradation, including FAK1 and the TLR adaptor TIRAP. Halving SOCS1 therefore also relieves that degradation: FAK1 rises, AKT and p70S6K phosphorylation increase, and TLR responses are elevated. This is a JAK-STAT-independent route to immune dysregulation, which is part of why the clinical picture is as pleiotropic as it is.
ubiquitin-protein transferase activity GO:0004842 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased ubiquitin-protein transferase activity (GO:0004842). GO:0004842 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Lymphocyte Hyperactivity
Show evidence (2 references)
PMID:34421895 SUPPORT Human Clinical
"reduced SOCS1 E3 ligase function was associated with increased FAK1 in immune cells, and increased AKT and p70 ribosomal protein S6 kinase phosphorylation"
Establishes the E3-ligase arm and its two measured downstream consequences.
PMID:34421895 SUPPORT Human Clinical
"We also found Toll-like receptor responses are increased in SOCS1 haploinsufficiency patients."
The innate-immune consequence of losing TIRAP degradation, and the reason this arm is not reducible to the T-cell phenotype.
Impaired B Cell Maturation
Low marginal zone and/or switched memory B cell counts in seven of ten patients, with IgG levels normal. The dissociation is the informative part: a normal IgG cannot be used to rule out the B-cell defect, and the defect is a maturation problem rather than a production one.
switched memory B cell CL:0000972 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves decreased switched memory B cell, annotated with class switched memory B cell (CL:0000972). CL:0000972 is a cell type from the Cell Ontology. ↓ DECREASED
Downstream
Humoral Immunodeficiency and Infection Susceptibility
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"The marginal zone and/or switched memory B cell counts were both low in seven patients"
Establishes the B-cell maturation defect with an explicit denominator in the founding ten-patient cohort.
Loss of Self-Tolerance and Autoimmunity
The autoimmune arm. Early-onset autoimmune disease is the presenting problem in most reported patients - autoimmune cytopenias prominently, with thyroiditis, nephritis, hepatitis and lupus-like features also described. The founding study frames the disease explicitly as a failure of a self-tolerance checkpoint.
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"Hence, SOCS1 haploinsufficiency causes a dominantly inherited predisposition to early onset autoimmune diseases related to cytokine hypersensitivity of immune cells."
The authors' concluding statement linking the molecular defect to the autoimmune phenotype.
Humoral Immunodeficiency and Infection Susceptibility
The immunodeficient arm - real, but narrower than the disease name suggests, and this entry initially overstated it. In the founding cohort of ten patients, none had infectious complications except one with recurrent bronchopulmonary infection, and IgG levels were normal. What that cohort does show is a maturation defect without a functional antibody deficit: marginal zone and/or switched memory B cells were low in seven of ten. Hypogammaglobulinaemia and CVID-like presentations are reported elsewhere in the literature and in the OMIM definition, so the arm is not fictional - but it is not the founding cohort's finding, and the entry should not read as if it were. A candidate route now exists for the part that is real: reduced STAT3 phosphorylation with falling Th17 cells is the same axis whose loss causes infection susceptibility in STAT3 loss-of-function disease. The incoming edge stays INDIRECT_UNKNOWN_INTERMEDIATES because that link is inferred from the shared signalling lesion rather than demonstrated in these patients.
Show evidence (3 references)
PMID:34421895 SUPPORT Human Clinical
"which demonstrates the clinical spectrum spans from autoimmunity to infections and malignancy"
Establishes that infection susceptibility, not only autoimmunity, is part of the reported spectrum.
PMID:33087723 SUPPORT Human Clinical
"whereas one (B2) developed Hodgkin lymphoma. None had infectious complications"
Qualifies the arm rather than supporting it: infection was absent in nine of ten founding patients, which is why this is PARTIAL and why the entry does not read as if infection were a general feature. The cached sentence continues "with the exception of recurrent bronchopulmonary infections in B1", hyphen-split across a line in the PDF extraction, so the quote is extended backward into the preceding clause rather than forward across the break.
PMID:33087723 SUPPORT Human Clinical
"The marginal zone and/or switched memory B cell counts were both low in seven patients"
The B-cell maturation defect - low marginal zone and/or switched memory B cells in seven of ten - which is what the founding cohort shows in place of a functional antibody deficiency. Extended from a fragment that began mid-sentence and did not say which counts were low.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for SOCS1 Haploinsufficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Blood 2
Autoimmune Cytopenia FREQUENT Autoimmune hemolytic anemia HP:0001890 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autoimmune hemolytic anemia (HP:0001890). HP:0001890 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33087723 SUPPORT Human Clinical
"we identify heterozygous, autosomal-dominant, germline loss-of-function mutations in the SOCS1 gene in ten patients from five unrelated families with early onset autoimmune manifestations"
Establishes early-onset autoimmune manifestations in the founding cohort. The specific cytopenia types are named in the OMIM/MONDO disease definition rather than in this abstract.
PMID:33087723 SUPPORT Human Clinical
"Five patients (A1, A2, B1, C1, and E2) had autoimmune cytopenia"
The explicit denominator behind the FREQUENT band - five of the ten founding patients. Carried as its own evidence item because a frequency is a separate quantitative claim from the disease-phenotype association above it. Granularity caveat, recorded here because this is where the band is justified: the count of five is for autoimmune cytopenia as a composite category, which includes immune thrombocytopenia, while this phenotype is bound to the narrower HP:0001890 Autoimmune hemolytic anemia. HPO has no autoimmune-cytopenia term, so 50% is a ceiling for AIHA specifically rather than its measured frequency, and the source does not decompose the five.
Hypogammaglobulinaemia Decreased circulating immunoglobulin concentration HP:0004313 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogammaglobulinaemia, annotated with Decreased circulating immunoglobulin concentration (HP:0004313). HP:0004313 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34421895 SUPPORT Human Clinical
"common variable immunodeficiency (CVID)-like phenotype with hypogammaglobulinemia, T-cell lymphopenia and granulomatous lymphocytic interstitial lung disease (GLILD) in P3"
Documents hypogammaglobulinaemia as an observed presentation, with the CVID-like context that makes the humoral deficit explicit.
Cardiovascular 1
Benign Lymphoproliferation OCCASIONAL Lymphadenopathy HP:0002716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphadenopathy (HP:0002716). HP:0002716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"Two patients (B1, and C1) had benign lymphoproliferation"
Explicit 2/10 denominator for benign lymphoproliferation in the founding cohort.
Immune 1
Recurrent Infections OCCASIONAL HP:0002719 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34421895 SUPPORT Human Clinical
"which demonstrates the clinical spectrum spans from autoimmunity to infections and malignancy"
Documents infection as part of the reported clinical spectrum.
PMID:33087723 SUPPORT Human Clinical
"whereas one (B2) developed Hodgkin lymphoma. None had infectious complications"
Curated as PARTIAL because it qualifies rather than supports the phenotype: 1 of 10 patients in the founding cohort had infections at all, which is the basis for the OCCASIONAL band and for the description's caveat.
Other 4
Systemic Lupus Erythematosus OCCASIONAL HP:0002725 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Systemic lupus erythematosus (HP:0002725). HP:0002725 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"two patients (D1 and E1) met the diagnostic criteria for systemic lupus erythematosus"
Explicit 2/10 denominator, which maps to the OCCASIONAL band.
Hodgkin Lymphoma OCCASIONAL HP:0012189 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hodgkin lymphoma (HP:0012189). HP:0012189 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"whereas one (B2) developed Hodgkin lymphoma. None had infectious complications"
Explicit 1/10 denominator for Hodgkin lymphoma. The same sentence carries the infection denominator used above.
Reduced Marginal Zone and Switched Memory B Cells Decreased marginal zone B cell proportion HP:0030384 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased proportion of marginal zone B cells, annotated with Decreased marginal zone B cell proportion (HP:0030384). HP:0030384 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33087723 SUPPORT Human Clinical
"counts were both low in seven patients"
Documents the B-cell maturation defect in seven of ten founding patients.
PMID:33087723 SUPPORT Human Clinical
"low marginal zone and/or switch memory B-cell counts in three"
The same abnormality in asymptomatic carriers, which is why it is curated as a laboratory feature rather than as a disease-defining one.
Severe Dermatitis Inflammatory abnormality of the skin HP:0011123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dermatitis, annotated with Inflammatory abnormality of the skin (HP:0011123). HP:0011123 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38157076 SUPPORT Human Clinical
"we describe a patient with severe dermatitis, recurrent skin infections, and psoriatic arthritis that harbors a novel heterozygous mutation in SOCS1"
Documents the dermatological and articular presentation in a confirmed patient.
🧬

Genetic Associations

1
SOCS1 (Heterozygous germline loss-of-function variants in SOCS1 cause this syndrome. The gene is dosage-sensitive: because its product is an inhibitor, halving it releases signalling rather than reducing it, which is why a heterozygous null is sufficient and why the phenotype is one of excess. Penetrance is incomplete and quantified: of fifteen heterozygous carriers studied in the founding families, five - a third, including four adults - were clinically healthy. So an identified variant does not by itself predict disease in a relative, and a healthy adult carrier is a common finding rather than an anomaly to be explained away. Several of those carriers nonetheless had subclinical immunological abnormalities, which is why "healthy" here means clinically unaffected and not immunologically normal.)
Gene: SOCS1 hgnc:19383 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SOCS1 (hgnc:19383). hgnc:19383 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:33087723 SUPPORT Human Clinical
"were healthy carriers (33%). This incomplete clinical penetrance is frequently observed"
Quantifies the incomplete penetrance at 33% in the founding families, replacing an unqualified "penetrance is incomplete".
PMID:34421895 SUPPORT Human Clinical
"Suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator of cytokine signaling, and has recently been associated with a novel IEI."
Establishes the gene-disease relationship and SOCS1's regulatory role.
PMID:34421895 SUPPORT Human Clinical
"Of patients described to date, it is apparent that SOCS1 haploinsufficiency has a pleiotropic effect in humans."
Supports the pleiotropy that follows from disinhibiting a pathway shared by many cytokines.
💊

Medical Actions

2
JAK Inhibition
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
The mechanistically matched therapy. Ruxolitinib, a JAK1/JAK2 inhibitor, reverses the increased STAT activation of patient lymphocytes in vitro - it substitutes pharmacologically for the brake the patient's genome no longer supplies. Curated against the cytokine-hypersensitivity node because that is the step it acts on. Note the evidence cited here is the in vitro reversal, not a clinical trial outcome.
Mechanism Target:
INHIBITS Cytokine Hypersensitivity with Increased STAT Activation — JAK1/JAK2 inhibition blocks the signalling step that SOCS1 normally restrains, returning STAT activation toward normal.
Show evidence (1 reference)
PMID:33087723 SUPPORT In Vitro
"patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-γ, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib"
Demonstrates that JAK inhibition reverses the specific defect in patient cells, which is the mechanistic basis for the treatment link.
Targeted Cytokine Blockade
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
A narrower alternative, and an instructive one. Despite a broad hyper-response across multiple cytokine pathways, one reported patient's disease responded markedly to IL4Rα and IL-17 blockade. That a two-cytokine intervention controls a pan-cytokine signalling defect suggests the clinical phenotype in a given patient is driven by a narrower set of axes than the laboratory abnormality implies - which matters, because targeted biologics avoid the broad immunosuppression of JAK inhibition.
Mechanism Target:
INHIBITS Loss of Self-Tolerance and Autoimmunity — Blocking IL4Rα and IL-17 signalling suppressed the autoinflammatory manifestations without correcting the underlying signalling defect.
Show evidence (1 reference)
PMID:38157076 SUPPORT Human Clinical
"Despite this broad hyper-response across multiple cytokine pathways in SOCS1 haploinsufficiency, the patient's clinical disease was markedly responsive to targeted IL4Rα- and IL17-blocking therapy."
Documents clinical response to targeted blockade in a confirmed patient.
🔬

Diagnosis

1
Molecular Genetic Testing of SOCS1
Sequencing of SOCS1. Worth considering in early-onset autoimmunity - particularly autoimmune cytopenias with a family history - and in immunodeficiency that sits oddly alongside autoimmune disease, since it is the combination rather than either half that points here. Incomplete penetrance means a variant found in an asymptomatic parent does not exclude causation.
Genetic Testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"The study of familial autoimmune diseases can reveal pathophysiological mechanisms involved in more common autoimmune diseases."
Supports genetic testing of familial early-onset autoimmunity as the route by which this disease is identified.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from SOCS1 Haploinsufficiency:

Common variable immunodeficiency
Overlapping Features Part of the reported SOCS1 spectrum resembles CVID - hypogammaglobulinaemia with infection susceptibility - so a CVID label can be where these patients stop rather than where they should. The discriminator is the accompanying early-onset autoimmunity and the family history, since CVID is a clinical diagnosis of exclusion.
Distinguishing Features
  • SOCS1 haploinsufficiency pairs immunodeficiency with prominent early-onset autoimmunity
  • Autosomal dominant transmission with incomplete penetrance, versus mostly sporadic CVID
  • Patient cells show increased STAT activation to multiple cytokines, reversible by JAK inhibition
Show evidence (1 reference)
PMID:34421895 SUPPORT Human Clinical
"which demonstrates the clinical spectrum spans from autoimmunity to infections and malignancy"
Establishes that the spectrum includes the infection-prone presentations that overlap CVID.
Other JAK-STAT pathway inborn errors of immunity
Overlapping Features STAT1 and STAT3 gain-of-function disorders reach a similar place from the other direction - by activating the signal rather than removing its brake - and also present with combined autoimmunity and immunodeficiency responsive to JAK inhibition. The KB's PTPN2-haploinsufficiency literature describes an analogous brake-loss disease. Distinguishing them is molecular rather than clinical.
Distinguishing Features
  • STAT1/STAT3 GOF activate the signalling molecule; SOCS1 haploinsufficiency removes its inhibitor
  • All can respond to JAK inhibition, so treatment response does not discriminate between them
Show evidence (1 reference)
PMID:33087723 SUPPORT Human Clinical
"The intracellular protein SOCS1 is known to downregulate cytokine signaling by inhibiting the JAK-STAT pathway."
Curated as PARTIAL because it establishes where SOCS1 sits in the pathway - the basis for the comparison - without itself comparing the diseases.
{ }

Source YAML

click to show 
name: SOCS1 Haploinsufficiency
creation_date: "2026-08-21T00:00:00Z"
category: Mendelian
description: >-
  Autoinflammatory syndrome with immunodeficiency (OMIM 619375) is an autosomal
  dominant inborn error of immunity caused by heterozygous loss-of-function variants
  in SOCS1, with incomplete penetrance.

  SOCS1 is the negative-feedback brake on JAK-STAT signalling. Losing one functional
  copy does not remove a cytokine or a receptor - it removes the off-switch, so cells
  respond excessively to cytokines that are present at ordinary levels. Patient
  lymphocytes show increased STAT activation to interferon-gamma, IL-2 and IL-4, and
  the excess is reversed in vitro by a JAK1/JAK2 inhibitor.

  The resulting disease is simultaneously autoimmune and immunodeficient, which is
  the feature that makes it worth curating as its own entity rather than as an
  autoimmunity syndrome. The reported spectrum runs from autoimmune cytopenias,
  thyroiditis, nephritis and lupus-like disease through hypogammaglobulinaemia and
  recurrent infection to malignancy - all from one gene, in a dosage-sensitive
  pathway whose job is restraint rather than activation.
disease_term:
  preferred_term: autoinflammatory syndrome with immunodeficiency
  term:
    id: MONDO:0800130
    label: autoinflammatory syndrome with immunodeficiency
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Autosomal dominant with incomplete penetrance. Disease arises from haploinsufficiency
    - one functional allele does not supply enough SOCS1 to restrain JAK-STAT signalling -
    rather than from a dominant-negative effect.
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "by whole-exome/genome sequencing we identify heterozygous, autosomal-dominant,
      germline loss-of-function mutations in the SOCS1 gene in ten patients from five
      unrelated families with early onset autoimmune manifestations"
    explanation: >-
      Establishes the inheritance pattern, the variant class, and the size of the founding
      cohort.

pathophysiology:
- name: Heterozygous SOCS1 Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Germline heterozygous loss-of-function variants in SOCS1. Reported alleles include
    frameshifts producing complete loss of protein expression from the affected allele;
    one such variant, c.202_203delAC (p.Thr68fsAla*49), was shown to abolish the
    protein's ability to inhibit JAK-STAT signalling when expressed in vitro.
  downstream:
  - target: Loss of JAK-STAT Negative Feedback
    causal_link_type: DIRECT
  - target: Loss of SOCS-Box E3 Ligase Function
    causal_link_type: DIRECT
    description: >-
      The same halved gene relieves both of SOCS1's activities. The SH2 domain stops
      inhibiting JAK and the SOCS-box stops assembling its E3 ligase; neither arm is
      downstream of the other.
  evidence:
  - reference: PMID:38157076
    reference_title: "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The variant, c.202_203delAC, generates a frameshift in SOCS1,
      p.Thr68fsAla*49, which leads to complete loss of protein expression."
    explanation: Documents a specific frameshift allele and confirms it is a true null.

- name: Loss of JAK-STAT Negative Feedback
  conforms_to: "jak_stat_pathway_activation#Loss of SOCS-Mediated Negative Feedback"
  biological_scale: MOLECULAR
  description: >-
    SOCS1 is an intracellular inhibitor of the JAK-STAT pathway - a brake, not a signal.
    Haploinsufficiency therefore does not alter what cytokines are present; it alters how
    strongly cells answer them. The mutant protein fails to perform the inhibition that
    wild-type SOCS1 does.
  biological_processes:
  - preferred_term: negative regulation of cytokine-mediated signaling pathway
    term:
      id: GO:0001960
      label: negative regulation of cytokine-mediated signaling pathway
    modifier: DECREASED
  downstream:
  - target: Cytokine Hypersensitivity with Increased STAT Activation
    causal_link_type: DIRECT
  - target: Reduced STAT3 Phosphorylation
    causal_link_type: DIRECT
    description: >-
      The same loss of feedback that raises STAT1 lowers STAT3. Both are downstream of the
      brake rather than of each other, which is why they are drawn as sibling arms.
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The intracellular protein SOCS1 is known to downregulate cytokine signaling
      by inhibiting the JAK-STAT pathway."
    explanation: Establishes SOCS1's normal function as the brake whose loss defines this disease.
  - reference: PMID:38157076
    reference_title: "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Unlike WT SOCS1, Thr68fs SOCS1 fails to inhibit JAK-STAT signaling when
      expressed in vitro."
    explanation: Direct functional demonstration that the variant protein cannot inhibit the pathway.

- name: Cytokine Hypersensitivity with Increased STAT Activation
  conforms_to: "jak_stat_pathway_activation#Constitutive STAT Activation and Nuclear Translocation"
  biological_scale: CELLULAR
  description: >-
    The central defect, and the one that is directly measurable in patients. Patient
    lymphocytes show increased STAT activation in response to interferon-gamma, IL-2 and
    IL-4 - three cytokines with different receptors and different downstream programmes,
    which is why the disease is pleiotropic rather than confined to one axis. Monocyte
    subpopulations are redistributed and hyper-responsive across multiple cytokine
    pathways.

    The hypersensitivity is not uniform across STATs, and that matters. STAT1
    phosphorylation is enhanced to a degree comparable with STAT1 gain-of-function
    disease, but STAT3 phosphorylation is REDUCED, with a concurrent fall in Th17 cells.
    So losing the brake does not simply turn everything up: the disease overlaps
    clinically with both STAT1 gain-of-function and STAT3 loss-of-function, and a
    description of it as global cytokine hyper-responsiveness is incomplete.
  biological_processes:
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
  cell_types:
  - preferred_term: lymphocyte
    term:
      id: CL:0000542
      label: lymphocyte
  downstream:
  - target: Lymphocyte Hyperactivity
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patient-derived lymphocytes exhibit increased STAT activation in vitro in
      response to interferon-γ, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor
      ruxolitinib"
    explanation: >-
      Demonstrates the hypersensitivity across three distinct cytokines and establishes its
      pharmacological reversibility, which is the basis of the treatment link below.
  - reference: PMID:38157076
    reference_title: "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The peripheral immune signature from this patient was marked by a
      redistribution of monocyte sub-populations and hyper-responsiveness to multiple
      cytokines."
    explanation: Extends the hypersensitivity beyond lymphocytes to the monocyte compartment.
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function
      mutations, and STAT3 phosphorylation is similarly reduced with concurrent reduction
      of Th17 cells."
    explanation: >-
      Curated as PARTIAL against the node's framing rather than as plain support: it
      establishes the hypersensitivity for STAT1 while showing the opposite for STAT3, so
      it qualifies the node as much as it supports it.
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced SOCS1 shows clinical overlaps with different monogenic IEIs, such as
      STAT3LOF and STAT1GOF"
    explanation: >-
      The clinical corollary of the split STAT phenotype, and the reason the disease
      resembles two opposite monogenic disorders at once.

- name: Lymphocyte Hyperactivity
  biological_scale: CELLULAR
  description: >-
    Cytokine hypersensitivity translates into a broad set of immune abnormalities
    consistent with lymphocytes that are too easily activated. This is the node from
    which the disease's two apparently opposite arms both descend.
  downstream:
  - target: Defective Regulatory T Cell Compartment
    causal_link_type: DIRECT
  - target: Impaired B Cell Maturation
    causal_link_type: DIRECT
  - target: Loss of Self-Tolerance and Autoimmunity
    causal_link_type: DIRECT
  - target: Humoral Immunodeficiency and Infection Susceptibility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This effect is associated with a series of in vitro and in vivo immune
      abnormalities consistent with lymphocyte hyperactivity."
    explanation: Establishes lymphocyte hyperactivity as the consequence of cytokine hypersensitivity.

- name: Defective Regulatory T Cell Compartment
  biological_scale: CELLULAR
  description: >-
    The cellular mechanism for the tolerance failure, which the hyperactivity node cannot
    supply on its own. Patients have a reduced frequency of CD4+CD25+FOXP3+ Tregs, lower
    expression of FOXP3 and HELIOS, and moderately but significantly reduced suppressive
    activity. The reduction is not an artefact of memory CD4 expansion. This matters
    directionally: a disease of excess signalling also removes the cells whose job is to
    restrain it, so the two arms compound rather than merely coexist.
  cell_types:
  - preferred_term: CD4+CD25+FOXP3+ regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
    modifier: DECREASED
  downstream:
  - target: Loss of Self-Tolerance and Autoimmunity
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This reduction in T regs frequency was not due to the expansion of memory
      CD4 T cells"
    explanation: >-
      Establishes the Treg frequency reduction in patients and excludes the trivial
      explanation that it reflects expansion of another CD4 compartment.
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally regulatory T cells are reduced in most SOCS1"
    explanation: >-
      Independent corroboration in a second patient series, which is why this is curated
      as a mechanism node rather than a single-cohort observation.

- name: Reduced STAT3 Phosphorylation
  biological_scale: MOLECULAR
  description: >-
    The finding that breaks the uniform-hypersensitivity framing. Losing a JAK-STAT brake
    does not raise every STAT equally: STAT1 phosphorylation is enhanced, comparably with
    STAT1 gain-of-function mutations, but STAT3 phosphorylation is reduced. A brake whose
    removal lowers one of its own substrates is not behaving as a simple brake, which is
    why this arm is modelled separately from the hypersensitivity node rather than as part
    of it.
  biological_processes:
  - preferred_term: STAT3 tyrosine phosphorylation
    term:
      id: GO:0007260
      label: tyrosine phosphorylation of STAT protein
    modifier: DECREASED
  downstream:
  - target: Th17 Compartment Reduction
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "STAT1 phosphorylation is enhanced, comparably with STAT1 gain-of-function
      mutations, and STAT3 phosphorylation is similarly reduced with concurrent reduction
      of Th17 cells."
    explanation: >-
      States both halves of the asymmetry, which is what makes "cytokine hypersensitivity"
      an incomplete description of the molecular phenotype.
- name: Th17 Compartment Reduction
  biological_scale: CELLULAR
  description: >-
    The cellular consequence of the reduced STAT3 signal, STAT3 being required for Th17
    differentiation. A reduced Th17 compartment is a plausible route to the
    infection-susceptibility arm whose intermediates the entry otherwise leaves unknown,
    so the edge below is curated as a candidate explanation rather than an established
    one: the two cohorts disagree about Th17, which is recorded as a discussion rather
    than resolved here.
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
    modifier: DECREASED
  biological_processes:
  - preferred_term: T-helper 17 cell differentiation
    term:
      id: GO:0072539
      label: T-helper 17 cell differentiation
    modifier: DECREASED
  downstream:
  - target: Humoral Immunodeficiency and Infection Susceptibility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Curated as a candidate route, not an established one. Th17 cells defend mucosal
      surfaces against extracellular bacteria and fungi, so their loss is a mechanistically
      coherent contributor to the infection arm - but the Th17 finding itself is disputed
      between the two cohorts, so the edge is left indirect rather than asserted as the
      explanation.
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "STAT3 phosphorylation is similarly reduced with concurrent reduction
      of Th17 cells."
    explanation: >-
      Ties the Th17 fall to the reduced STAT3 signal in the same patients.

- name: Loss of SOCS-Box E3 Ligase Function
  biological_scale: MOLECULAR
  description: >-
    The second of SOCS1's two domains, and the arm the entry previously omitted entirely -
    modelling a two-domain protein as a one-domain brake. Beyond the SH2-mediated JAK
    inhibition, SOCS1 uses its C-terminal SOCS-box to assemble a Cullin5-Rbx2 E3 ligase
    that ubiquitinates substrates for degradation, including FAK1 and the TLR adaptor
    TIRAP. Halving SOCS1 therefore also relieves that degradation: FAK1 rises, AKT and
    p70S6K phosphorylation increase, and TLR responses are elevated. This is a
    JAK-STAT-independent route to immune dysregulation, which is part of why the clinical
    picture is as pleiotropic as it is.
  molecular_functions:
  - preferred_term: ubiquitin-protein transferase activity
    term:
      id: GO:0004842
      label: ubiquitin-protein transferase activity
    modifier: DECREASED
  downstream:
  - target: Lymphocyte Hyperactivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced SOCS1 E3 ligase function was associated with increased FAK1 in
      immune cells, and increased AKT and p70 ribosomal protein S6 kinase phosphorylation"
    explanation: Establishes the E3-ligase arm and its two measured downstream consequences.
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also found Toll-like receptor responses are increased in SOCS1
      haploinsufficiency patients."
    explanation: >-
      The innate-immune consequence of losing TIRAP degradation, and the reason this arm
      is not reducible to the T-cell phenotype.

- name: Impaired B Cell Maturation
  biological_scale: CELLULAR
  description: >-
    Low marginal zone and/or switched memory B cell counts in seven of ten patients, with
    IgG levels normal. The dissociation is the informative part: a normal IgG cannot be
    used to rule out the B-cell defect, and the defect is a maturation problem rather than
    a production one.
  cell_types:
  - preferred_term: switched memory B cell
    term:
      id: CL:0000972
      label: class switched memory B cell
    modifier: DECREASED
  downstream:
  - target: Humoral Immunodeficiency and Infection Susceptibility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The marginal zone and/or switched memory B cell counts were both low in
      seven patients"
    explanation: >-
      Establishes the B-cell maturation defect with an explicit denominator in the
      founding ten-patient cohort.

- name: Loss of Self-Tolerance and Autoimmunity
  biological_scale: ORGANISM
  description: >-
    The autoimmune arm. Early-onset autoimmune disease is the presenting problem in most
    reported patients - autoimmune cytopenias prominently, with thyroiditis, nephritis,
    hepatitis and lupus-like features also described. The founding study frames the
    disease explicitly as a failure of a self-tolerance checkpoint.
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hence, SOCS1 haploinsufficiency causes a dominantly inherited predisposition
      to early onset autoimmune diseases related to cytokine hypersensitivity of immune
      cells."
    explanation: >-
      The authors' concluding statement linking the molecular defect to the autoimmune
      phenotype.

- name: Humoral Immunodeficiency and Infection Susceptibility
  biological_scale: ORGANISM
  description: >-
    The immunodeficient arm - real, but narrower than the disease name suggests, and
    this entry initially overstated it. In the founding cohort of ten patients, none had
    infectious complications except one with recurrent bronchopulmonary infection, and
    IgG levels were normal. What that cohort does show is a maturation defect without a
    functional antibody deficit: marginal zone and/or switched memory B cells were low in
    seven of ten. Hypogammaglobulinaemia and CVID-like presentations are reported
    elsewhere in the literature and in the OMIM definition, so the arm is not fictional -
    but it is not the founding cohort's finding, and the entry should not read as if it
    were.

    A candidate route now exists for the part that is real: reduced STAT3 phosphorylation
    with falling Th17 cells is the same axis whose loss causes infection susceptibility in
    STAT3 loss-of-function disease. The incoming edge stays
    INDIRECT_UNKNOWN_INTERMEDIATES because that link is inferred from the shared signalling
    lesion rather than demonstrated in these patients.
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which demonstrates the clinical spectrum spans from autoimmunity to
      infections and malignancy"
    explanation: >-
      Establishes that infection susceptibility, not only autoimmunity, is part of the
      reported spectrum.
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas one (B2) developed Hodgkin lymphoma. None had infectious
      complications"
    explanation: >-
      Qualifies the arm rather than supporting it: infection was absent in nine of ten
      founding patients, which is why this is PARTIAL and why the entry does not read as
      if infection were a general feature. The cached sentence continues "with the
      exception of recurrent bronchopulmonary infections in B1", hyphen-split across a
      line in the PDF extraction, so the quote is extended backward into the preceding
      clause rather than forward across the break.
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The marginal zone and/or switched memory B cell counts were both low in
      seven patients"
    explanation: >-
      The B-cell maturation defect - low marginal zone and/or switched memory B cells in
      seven of ten - which is what the founding cohort shows in place of a functional
      antibody deficiency. Extended from a fragment that began mid-sentence and did not
      say which counts were low.

phenotypes:
- category: Hematological
  name: Autoimmune Cytopenia
  frequency: FREQUENT
  description: >-
    Autoimmune cytopenias including immune thrombocytopenia and autoimmune haemolytic
    anaemia, frequently the presenting problem. Five of the ten patients in the founding
    cohort had autoimmune cytopenia - the explicit denominator this band is derived from,
    and the highest single-manifestation count in that series.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify heterozygous, autosomal-dominant, germline loss-of-function
      mutations in the SOCS1 gene in ten patients from five unrelated families with early
      onset autoimmune manifestations"
    explanation: >-
      Establishes early-onset autoimmune manifestations in the founding cohort. The
      specific cytopenia types are named in the OMIM/MONDO disease definition rather than
      in this abstract.
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients (A1, A2, B1, C1, and E2) had autoimmune cytopenia"
    explanation: >-
      The explicit denominator behind the FREQUENT band - five of the ten founding
      patients. Carried as its own evidence item because a frequency is a separate
      quantitative claim from the disease-phenotype association above it.

      Granularity caveat, recorded here because this is where the band is justified: the
      count of five is for autoimmune cytopenia as a composite category, which includes
      immune thrombocytopenia, while this phenotype is bound to the narrower HP:0001890
      Autoimmune hemolytic anemia. HPO has no autoimmune-cytopenia term, so 50% is a
      ceiling for AIHA specifically rather than its measured frequency, and the source
      does not decompose the five.

- category: Immunological
  name: Recurrent Infections
  description: >-
    Infection susceptibility is part of the reported spectrum but is the minor arm of it,
    and the entry should not read otherwise. In the founding ten-patient cohort only one
    patient had infectious complications at all - recurrent bronchopulmonary infections -
    and IgG levels were normal, while autoimmunity was near-universal. The disease is named
    for both arms because the spectrum spans them, not because they are equally frequent.

    The frequency band is derived from that explicit denominator (1 of 10). Bands are
    assigned in this entry only where a source gives an explicit count of that kind, which
    is the case for four phenotypes; everything else carries none.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which demonstrates the clinical spectrum spans from autoimmunity to
      infections and malignancy"
    explanation: Documents infection as part of the reported clinical spectrum.
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas one (B2) developed Hodgkin lymphoma. None had infectious
      complications"
    explanation: >-
      Curated as PARTIAL because it qualifies rather than supports the phenotype: 1 of 10
      patients in the founding cohort had infections at all, which is the basis for the
      OCCASIONAL band and for the description's caveat.

- category: Immunological
  name: Systemic Lupus Erythematosus
  description: >-
    Two of ten patients met full diagnostic criteria for SLE, with discoid lupus and
    lupus glomerulonephritis. Curated separately from the generic autoimmunity node
    because meeting classification criteria for a defined autoimmune disease is a
    stronger and differently actionable claim than "organ-specific autoimmunity".
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Systemic lupus erythematosus
    term:
      id: HP:0002725
      label: Systemic lupus erythematosus
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two patients (D1 and E1) met the diagnostic criteria for systemic lupus
      erythematosus"
    explanation: >-
      Explicit 2/10 denominator, which maps to the OCCASIONAL band.

- category: Hematological
  name: Benign Lymphoproliferation
  description: >-
    Lymphadenopathy and/or hepatosplenomegaly in two of ten patients - the reactive,
    non-malignant end of the lymphoproliferative spectrum this disease sits on, and the
    reason a node is not automatically a lymphoma here.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two patients (B1, and C1) had benign lymphoproliferation"
    explanation: >-
      Explicit 2/10 denominator for benign lymphoproliferation in the founding cohort.

- category: Neoplastic
  name: Hodgkin Lymphoma
  description: >-
    One patient in the founding cohort developed Hodgkin lymphoma. Curated because the
    malignant end of the lymphoproliferative spectrum changes surveillance, and because
    it is the clinical counterweight to treating this disease purely as autoimmunity.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hodgkin lymphoma
    term:
      id: HP:0012189
      label: Hodgkin lymphoma
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas one (B2) developed Hodgkin lymphoma. None had infectious
      complications"
    explanation: >-
      Explicit 1/10 denominator for Hodgkin lymphoma. The same sentence carries the
      infection denominator used above.

- category: Immunological
  name: Reduced Marginal Zone and Switched Memory B Cells
  description: >-
    Low marginal zone and/or switched memory B-cell counts, present in seven of the ten
    founding patients while IgG remained normal - a maturation defect that does not
    translate into a measured antibody deficiency in that cohort. The same abnormality was
    found in three of four asymptomatic carriers phenotyped, so it is not by itself
    sufficient for disease.
  phenotype_term:
    preferred_term: Decreased proportion of marginal zone B cells
    term:
      id: HP:0030384
      label: Decreased marginal zone B cell proportion
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "counts were both low in seven patients"
    explanation: Documents the B-cell maturation defect in seven of ten founding patients.
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "low marginal zone and/or switch memory B-cell counts in three"
    explanation: >-
      The same abnormality in asymptomatic carriers, which is why it is curated as a
      laboratory feature rather than as a disease-defining one.

- category: Dermatological
  name: Severe Dermatitis
  description: >-
    Severe dermatitis with recurrent skin infections, reported alongside psoriatic
    arthritis in a patient whose disease responded to IL4Rα and IL-17 blockade.
  phenotype_term:
    preferred_term: Dermatitis
    term:
      id: HP:0011123
      label: Inflammatory abnormality of the skin
  evidence:
  - reference: PMID:38157076
    reference_title: "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we describe a patient with severe dermatitis, recurrent skin infections, and
      psoriatic arthritis that harbors a novel heterozygous mutation in SOCS1"
    explanation: Documents the dermatological and articular presentation in a confirmed patient.

- category: Immunological
  name: Hypogammaglobulinaemia
  description: >-
    Reduced circulating immunoglobulin, reported as part of a CVID-like presentation
    together with T-cell lymphopenia and granulomatous lymphocytic interstitial lung
    disease. This is the phenotype the Humoral Immunodeficiency node is named for, and
    it is what makes the immunodeficiency arm more than an inference from infection
    counts: a measurable antibody deficit sits alongside the hyperactivity elsewhere.
    Recorded without a frequency band - the source describes it in a single patient of
    a small series as one of several alternative presentations, not as a proportion of
    the cohort.
  phenotype_term:
    preferred_term: Hypogammaglobulinaemia
    term:
      id: HP:0004313
      label: Decreased circulating immunoglobulin concentration
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "common variable immunodeficiency (CVID)-like phenotype with
      hypogammaglobulinemia, T-cell lymphopenia and granulomatous lymphocytic interstitial
      lung disease (GLILD) in P3"
    explanation: Documents hypogammaglobulinaemia as an observed presentation, with the
      CVID-like context that makes the humoral deficit explicit.

genetic:
- name: SOCS1
  gene_term:
    preferred_term: SOCS1
    term:
      id: hgnc:19383
      label: SOCS1
  relationship_type: CAUSATIVE
  association: >-
    Heterozygous germline loss-of-function variants in SOCS1 cause this syndrome. The
    gene is dosage-sensitive: because its product is an inhibitor, halving it releases
    signalling rather than reducing it, which is why a heterozygous null is sufficient
    and why the phenotype is one of excess. Penetrance is incomplete and quantified: of
    fifteen heterozygous carriers studied in the founding families, five - a third,
    including four adults - were clinically healthy. So an identified variant does not by
    itself predict disease in a relative, and a healthy adult carrier is a common finding
    rather than an anomaly to be explained away. Several of those carriers nonetheless had
    subclinical immunological abnormalities, which is why "healthy" here means clinically
    unaffected and not immunologically normal.
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "were healthy carriers (33%). This incomplete clinical penetrance is
      frequently observed"
    explanation: >-
      Quantifies the incomplete penetrance at 33% in the founding families, replacing an
      unqualified "penetrance is incomplete".
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator of
      cytokine signaling, and has recently been associated with a novel IEI."
    explanation: Establishes the gene-disease relationship and SOCS1's regulatory role.
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of patients described to date, it is apparent that SOCS1 haploinsufficiency
      has a pleiotropic effect in humans."
    explanation: >-
      Supports the pleiotropy that follows from disinhibiting a pathway shared by many
      cytokines.

diagnosis:
- name: Molecular Genetic Testing of SOCS1
  description: >-
    Sequencing of SOCS1. Worth considering in early-onset autoimmunity - particularly
    autoimmune cytopenias with a family history - and in immunodeficiency that sits
    oddly alongside autoimmune disease, since it is the combination rather than either
    half that points here. Incomplete penetrance means a variant found in an
    asymptomatic parent does not exclude causation.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The study of familial autoimmune diseases can reveal pathophysiological
      mechanisms involved in more common autoimmune diseases."
    explanation: >-
      Supports genetic testing of familial early-onset autoimmunity as the route by which
      this disease is identified.

treatments:
- name: JAK Inhibition
  description: >-
    The mechanistically matched therapy. Ruxolitinib, a JAK1/JAK2 inhibitor, reverses the
    increased STAT activation of patient lymphocytes in vitro - it substitutes
    pharmacologically for the brake the patient's genome no longer supplies. Curated
    against the cytokine-hypersensitivity node because that is the step it acts on. Note
    the evidence cited here is the in vitro reversal, not a clinical trial outcome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Cytokine Hypersensitivity with Increased STAT Activation
    treatment_effect: INHIBITS
    description: >-
      JAK1/JAK2 inhibition blocks the signalling step that SOCS1 normally restrains,
      returning STAT activation toward normal.
    evidence:
    - reference: PMID:33087723
      reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "patient-derived lymphocytes exhibit increased STAT activation in vitro in
        response to interferon-γ, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor
        ruxolitinib"
      explanation: >-
        Demonstrates that JAK inhibition reverses the specific defect in patient cells,
        which is the mechanistic basis for the treatment link.

- name: Targeted Cytokine Blockade
  description: >-
    A narrower alternative, and an instructive one. Despite a broad hyper-response across
    multiple cytokine pathways, one reported patient's disease responded markedly to
    IL4Rα and IL-17 blockade. That a two-cytokine intervention controls a
    pan-cytokine signalling defect suggests the clinical phenotype in a given patient is
    driven by a narrower set of axes than the laboratory abnormality implies - which
    matters, because targeted biologics avoid the broad immunosuppression of JAK
    inhibition.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Loss of Self-Tolerance and Autoimmunity
    treatment_effect: INHIBITS
    description: >-
      Blocking IL4Rα and IL-17 signalling suppressed the autoinflammatory manifestations
      without correcting the underlying signalling defect.
    evidence:
    - reference: PMID:38157076
      reference_title: "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Despite this broad hyper-response across multiple cytokine pathways in
        SOCS1 haploinsufficiency, the patient's clinical disease was markedly responsive to
        targeted IL4Rα- and IL17-blocking therapy."
      explanation: Documents clinical response to targeted blockade in a confirmed patient.

differential_diagnoses:
- name: Common variable immunodeficiency
  description: >-
    Part of the reported SOCS1 spectrum resembles CVID - hypogammaglobulinaemia with
    infection susceptibility - so a CVID label can be where these patients stop rather
    than where they should. The discriminator is the accompanying early-onset
    autoimmunity and the family history, since CVID is a clinical diagnosis of exclusion.
  distinguishing_features:
  - SOCS1 haploinsufficiency pairs immunodeficiency with prominent early-onset autoimmunity
  - Autosomal dominant transmission with incomplete penetrance, versus mostly sporadic CVID
  - Patient cells show increased STAT activation to multiple cytokines, reversible by JAK inhibition
  evidence:
  - reference: PMID:34421895
    reference_title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which demonstrates the clinical spectrum spans from autoimmunity to
      infections and malignancy"
    explanation: Establishes that the spectrum includes the infection-prone presentations that overlap CVID.

- name: Other JAK-STAT pathway inborn errors of immunity
  description: >-
    STAT1 and STAT3 gain-of-function disorders reach a similar place from the other
    direction - by activating the signal rather than removing its brake - and also present
    with combined autoimmunity and immunodeficiency responsive to JAK inhibition. The
    KB's PTPN2-haploinsufficiency literature describes an analogous brake-loss disease.
    Distinguishing them is molecular rather than clinical.
  distinguishing_features:
  - STAT1/STAT3 GOF activate the signalling molecule; SOCS1 haploinsufficiency removes its inhibitor
  - All can respond to JAK inhibition, so treatment response does not discriminate between them
  evidence:
  - reference: PMID:33087723
    reference_title: "Early-onset autoimmunity associated with SOCS1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The intracellular protein SOCS1 is known to downregulate cytokine signaling
      by inhibiting the JAK-STAT pathway."
    explanation: >-
      Curated as PARTIAL because it establishes where SOCS1 sits in the pathway - the basis
      for the comparison - without itself comparing the diseases.

discussions:
- discussion_id: gap_th17_compartment_disagreement
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Reduced STAT3 Phosphorylation
  - pathophysiology#Th17 Compartment Reduction
  prompt: >-
    Is the Th17 compartment reduced in SOCS1 haploinsufficiency, and if so is that the
    route to the infection-susceptibility arm?
  rationale: >-
    The two patient series in this entry disagree, and the disagreement is curated rather
    than adjudicated because neither result is obviously the weaker one. Michniacki and
    colleagues report reduced STAT3 phosphorylation with a concurrent reduction of Th17
    cells; Hadjadj and colleagues, in the founding ten-patient cohort, explicitly looked
    and did not observe an imbalance in Th1, Th2, Th17 or T follicular helper cells. The
    cohorts differ in size, assay and whether CRISPR-edited primary T cells were used
    alongside patient cells, any of which could account for it. This is not a
    bookkeeping dispute: a reduced Th17 compartment is the most concrete available
    candidate for the intermediates on the INDIRECT_UNKNOWN_INTERMEDIATES edge into the
    immunodeficiency arm, so whether it is real determines whether that edge can be
    specified. It also bears on therapy, since IL-17 blockade has been used successfully
    in at least one patient - which is difficult to reconcile with Th17 already being
    depleted.
  proposed_experiments:
  - experiment_id: exp_socs1_th17_harmonized_assay
    name: Re-measure the Th17 compartment across both cohorts with a harmonised assay
    description: >-
      Apply one intracellular-cytokine and STAT3-phosphorylation protocol to patient
      samples from both series, stratified by treatment status at sampling, and pair it
      with IL-17 functional readouts. If Th17 reduction replicates only in patients
      already on immunosuppression it is iatrogenic rather than mechanistic; if it
      replicates in untreated patients, the immunodeficiency edge can be specified and
      the IL-17-blockade response needs a different explanation.

- discussion_id: gap_autoimmunity_and_immunodeficiency_from_one_defect
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Humoral Immunodeficiency and Infection Susceptibility
  prompt: >-
    How does a single defect that makes immune cells hypersensitive to cytokines produce
    immunodeficiency and hypogammaglobulinaemia alongside autoimmunity?
  rationale: >-
    The autoimmune arm follows straightforwardly from lymphocyte hyperactivity. The
    immunodeficient arm does not: a system that responds too strongly ought not to
    respond too little. Candidate explanations include activation-induced exhaustion or
    death of chronically stimulated lymphocytes, disruption of B-cell maturation by
    excess interferon signalling, or the immunodeficiency being partly iatrogenic in
    patients treated with immunosuppression for their autoimmunity - a confound that is
    hard to exclude in a disease whose autoimmune manifestations usually present first.
    Distinguishing these matters for whether JAK inhibition would be expected to improve
    or worsen the infection susceptibility.
  proposed_experiments:
  - experiment_id: exp_socs1_bcell_maturation_untreated
    name: B-cell maturation phenotyping in treatment-naive SOCS1 haploinsufficient patients
    description: >-
      Characterise B-cell subsets, class-switching and immunoglobulin levels in patients
      before any immunosuppressive therapy, and again on JAK inhibition. If
      hypogammaglobulinaemia is present pre-treatment it is intrinsic to the disease; if it
      emerges only after immunosuppression, the immunodeficient arm is substantially
      iatrogenic and the entry's causal chain should be revised.

- discussion_id: gap_broad_defect_narrow_therapy
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Cytokine Hypersensitivity with Increased STAT Activation
  prompt: >-
    Why did blocking just two cytokine axes control disease in a patient whose cells were
    hyper-responsive to many?
  rationale: >-
    Patient cells show excess STAT activation to interferon-gamma, IL-2, IL-4 and more,
    yet one patient's clinical disease responded markedly to IL4Rα and IL-17 blockade
    alone. Either the laboratory hyper-responsiveness overstates which axes actually drive
    tissue pathology, or the driving axes differ between patients and this patient's
    happened to be those two. The distinction is directly actionable: the first would
    justify trying targeted biologics before broad JAK inhibition, the second would mean
    the choice has to be made per patient from the phenotype. With single-patient
    evidence, neither is established.
  proposed_experiments:
  - experiment_id: exp_socs1_axis_to_phenotype_mapping
    name: Map per-patient cytokine hyper-responsiveness against clinical manifestations
    description: >-
      Across a SOCS1 cohort, measure STAT activation per cytokine axis and score it against
      each patient's dominant clinical features. A consistent axis-to-phenotype mapping
      would support choosing targeted blockade rationally rather than defaulting to JAK
      inhibition.

notes: >-
  No GeneReviews chapter exists for SOCS1 or for this disease. Verified by search:
  "SOCS1 GeneReviews[All Fields]" returns zero results.

  Frequency bands are assigned only where a cited source gives an explicit denominator.
  Four phenotypes carry OCCASIONAL on that basis, each derived from a counted fraction of
  the ten-patient founding cohort. The rest carry none: the founding cohort is ten
  patients from five families, the literature since is case reports and small series, and
  the reviews describe the phenotype as pleiotropic and variable rather than giving
  proportions. Hypogammaglobulinaemia in particular is described as one of several
  alternative presentations in a single patient, which is a phenotype observation and not
  a rate.

  PMID:36890397 ("Phenotypic Variability of SOCS1 Haploinsufficiency") was fetched and is
  topically central, but it caches with an empty abstract, so nothing in this entry is
  quoted from it and it is not listed in references. It is a good candidate for
  re-fetching if full text becomes available.

  Deep-research provenance: the claude_code report resolved 16 of 17 references
  (confabulation_rate 0.059). The single unresolved identifier is a markdown-link parsing
  artefact - "DOI:10.1371/journal.pone.0162111](https://journals.plos.org" - rather than a
  fabricated DOI, and the report also carried one unsupported quote attributed to
  PMC:PMC11070515. Neither is used here; the reference set was assembled by direct PubMed
  search and every snippet is quoted from the cached record.

references:
- reference: PMID:33087723
  title: Early-onset autoimmunity associated with SOCS1 haploinsufficiency.
- reference: PMID:34421895
  title: "One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1
    Haploinsufficiency."
- reference: PMID:38157076
  title: IL4Ralpha and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency.
📚

References & Deep Research

References

3
PMID:33087723
Early-onset autoimmunity associated with SOCS1 haploinsufficiency.
No top-level findings curated for this source.
PMID:34421895
One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency.
No top-level findings curated for this source.
PMID:38157076
IL4Ralpha and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
SOCS1 Haploinsufficiency — Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 23 citations 2026-08-21T16:29:54.030501

SOCS1 Haploinsufficiency — Comprehensive Research Report

1. Disease Information

Overview. SOCS1 (suppressor of cytokine signaling 1) haploinsufficiency (SOCS1-HI) is a recently delineated, autosomal dominant inborn error of immunity (IEI) caused by heterozygous loss-of-function variants in SOCS1, encoding a key intracellular negative regulator of JAK/STAT cytokine signaling. Loss of one functional SOCS1 allele produces cytokine hypersensitivity (especially to IFN-γ, IL-2, IL-4, IL-6) and a strikingly pleiotropic clinical picture spanning early-onset autoimmunity, autoinflammation, lymphoproliferation, atopy, and increased infection susceptibility. It was first formally described as a Mendelian disease entity in 2020 (Hadjadj et al., Nat Commun 2020; PMC copy: PMC7578789), although the underlying biology had been predicted by SOCS1-knockout mouse work two decades earlier (Naka et al. and Starr et al., 1998; Alexander et al. 1999, PMID:10490099; Marine et al. 1999, PMID:10490100).

Key identifiers: - Gene: SOCS1, HGNC:19383, chromosome 16p13.13 (chr16:11,249,101–11,256,556, GRCh38) (GeneCards; ClinGen) - Orphanet: ORPHA "Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency" (Orphanet detail page 619948) - OMIM gene entry: SOCS1, 603597 (OMIM 603597) — a distinct phenotype MIM number for the haploinsufficiency syndrome has not been broadly confirmed in the sources searched - ClinGen: SOCS1 has 1 Gene-Disease Validity classification but, as of the current search, 0 Dosage Sensitivity classification on file (ClinGen SOCS1) - Falls under the broader IEI category of autoimmune lymphoproliferative immunodeficiencies (ALPID)* (PMC10499775)

Common synonyms/alternative names: SOCS1 insufficiency; SOCS1 deficiency (heterozygous); SOCS-1 haploinsufficiency; JAK/STAT gain-of-function-like syndrome due to SOCS1; early-onset autoimmunity–autoinflammation–immunodeficiency syndrome due to SOCS1 haploinsufficiency (Orphanet name).

Data source type. The evidence base is almost entirely individual patient-level case reports and small case series (5–10 patients per report), aggregated across international collaborative registries (a European ESID-affiliated SOCS1 study group and a US SOCS1 study group), culminating in a registry-based, population-level systematic review of 33 patients across 9 publications (Lancet Rheumatology 2024). There is no large aggregated disease-level registry comparable to those for common autoimmune diseases; essentially all quantitative statistics below derive from this pooled literature review of the (currently) small known patient population.

2. Etiology

Disease causal factor: SOCS1-HI is a monogenic, autosomal dominant condition. It is caused directly by heterozygous loss-of-function (LOF) germline variants in SOCS1 — frameshift, nonsense, missense (particularly in the SH2 and SOCS-box domains), and complete gene deletions (including microdeletions/CNVs removing one copy of 16p13.13) — that reduce functional SOCS1 protein dosage by ~50%, sufficient to disturb the stoichiometric balance of JAK/STAT negative feedback ("haploinsufficiency" model) (Nat Commun 2020; PMC11070515).

Genetic risk factors: - Reported pathogenic variants include: p.P123R (c.368C>G), SH2 domain missense; p.A9Pfs*76 (c.24delA), frameshift in the 5′ KIR region; p.M161Afs*46 (c.476_480dupGCCGC), frameshift in the SOCS box; p.R22W (c.64C>T), missense in the KIR region; p.Y154H (c.460T>C), SH2 domain missense — all with high CADD scores (>11.63) (PMC7578789) - A p.(Ala70Pro) [c.208G>C] variant segregating with a multi-generational family with neurological disease (PMC12628480) - Complete heterozygous chromosomal deletions of 16p13.13 encompassing SOCS1 (e.g., unmasked by SARS-CoV-2 infection in a pediatric patient) — interestingly, reports note complete gene deletions may produce a less severe phenotype than certain heterozygous C-terminal point variants, possibly reflecting dominant-negative effects of some missense/truncating alleles beyond simple dosage loss (PMC11070515; Springer 2022 case report) - Population tolerance: gnomAD v4.0 reports SOCS1 pLI = 0.12 and LOEUF = 1.47 (search results) — a relatively "tolerant" score in the general population metric, which sits in tension with the clinical LOF disease association and likely reflects incomplete penetrance plus the population database's limited power for a gene of this size/constraint profile. - Family segregation studies show identical variants produce markedly different phenotypes even within the same pedigree, indicating additional genetic/epigenetic modifiers are likely at play, though none have yet been formally identified.

Environmental risk factors / triggers: - Infection as a disease-unmasking trigger is a recurring and clinically important theme: SARS-CoV-2 infection precipitating immune thrombocytopenia, arthralgia/enthesitis, and multisystem inflammatory syndrome in children (MIS-C)-like presentations in carriers (PubMed 32853638; PMC11746893, two case reports) - Acute infections generally appear able to "unmask" underlying cytokine hypersensitivity, precipitating first presentation with cytopenia or autoinflammatory flares.

Protective factors: No specific genetic or environmental protective factors have been characterized in the literature searched; ~33% of identified mutation carriers remain clinically asymptomatic despite carrying the pathogenic variant and displaying immunological abnormalities on functional testing, implying unidentified modifying/protective factors (PMC7578789).

Gene-environment interaction: The clearest documented interaction is infection (particularly SARS-CoV-2) acting as a "second hit" precipitant of overt autoimmune/autoinflammatory disease in genetically susceptible (SOCS1+/-) individuals, consistent with a two-hit model in which baseline cytokine hypersensitivity is clinically silent until an inflammatory trigger occurs.

3. Phenotypes

SOCS1-HI shows extreme pleiotropy, involving essentially every major organ system. Onset is typically pediatric (median 7.5 years) but ranges into adulthood.

Hematologic / autoimmune cytopenias (most common presenting feature)

  • Immune thrombocytopenia (ITP) — HP:0001873 (Thrombocytopenia)
  • Autoimmune hemolytic anemia — HP:0001878 (Hemolytic anemia)
  • Evans syndrome (combined ITP + AIHA)
  • 5/10 index patients in the founding cohort had autoimmune cytopenia (PMC7578789)

Systemic/organ-specific autoimmunity

  • Systemic lupus erythematosus (SLE)-like disease — HP:0002960 (Autoimmunity), often with glomerulonephritis and discoid skin lesions; described as the single most common overall manifestation in the pooled registry review (Lancet Rheumatology 2024)
  • Autoimmune thyroiditis — HP:0100646
  • Coeliac disease — HP:0002608
  • Psoriasis / psoriasis-like lesions — HP:0100750
  • Spondyloarthritis / severe enthesitis — HP:0011729-adjacent; a pediatric case presented with severe enthesitis and bone marrow hypocellularity (Springer 2022)
  • Autoimmune hepatitis — HP:0001394; autoimmune pancreatitis

Autoinflammatory / granulomatous manifestations

  • Atopic disease: asthma, allergic rhinoconjunctivitis, atopic dermatitis (SOCS1-HI is distinguished from other genetic ALPS-like disorders by frequent atopic manifestations) (Lancet Rheumatology 2024)
  • Granulomatous-lymphocytic interstitial lung disease (GLILD), organizing pneumonia, granulomatous uveitis
  • Severe oral and upper gastrointestinal ulcerations, recurrent stomatitis (ACR abstract findings)

Gastrointestinal

  • Coeliac disease, Crohn's-like disease, chronic intestinal pseudo-obstruction, and a specifically described lymphocytic leiomyositis with CD8+ T-cell muscular infiltration causing intestinal obstructive symptoms, responsive to ruxolitinib (Springer 2023 intestinal spectrum paper)

Lymphoproliferative / neoplastic

  • Lymphadenopathy mimicking ALPS (autoimmune lymphoproliferative syndrome)
  • One documented case of Hodgkin lymphoma at age 34 evolving from chronic lymphoproliferation (PMC7578789)

Neurological (newly expanding phenotype, 2025)

  • Multiple sclerosis (relapsing-remitting, adult-onset, diagnosed age 35)
  • Autoimmune (limbic) encephalitis with anti-GAD antibodies and seizures (onset age 10)
  • Complex regional pain syndrome (CRPS) with reduced intraepidermal nerve fiber density (4.02/mm vs. normal cutoff of 8.4/mm), suggesting peripheral small-fiber neuropathy (PMC12628480)

Infectious susceptibility

  • Predominantly localized infections; severe bacterial infections reported in some patients (PMC11070515)
  • MIS-C-like presentation following SARS-CoV-2 in carriers (PubMed 32853638)

Phenotype characteristics

  • Age of onset: median 7.5 years (range 2–44 years) in the founding cohort (PMC7578789); some patients (e.g., MS) present in adulthood
  • Severity/progression: highly variable — ranges from asymptomatic carriers (33% of gene carriers) to severe multi-organ, treatment-refractory disease
  • Sex bias: autoimmune manifestations predominate in females, mirroring the female bias of SLE, and consistent with heterozygous mouse model data (PMC11070515)
  • Penetrance: incomplete — approximately two-thirds of variant carriers are symptomatic; penetrance is higher in females than males (Lancet Rheumatology 2024)

Quality of life

No dedicated QoL instrument studies (EQ-5D/SF-36) were identified for this rare, newly described condition; qualitative case reports describe substantial disease burden from chronic cytopenia, refractory arthralgia/enthesitis, and neurological complications (e.g., CRPS causing debilitating pain episodes).

4. Genetic/Molecular Information

Causal gene: SOCS1 (HGNC:19383; OMIM 603597), 16p13.13.

Variant spectrum and classification: | Variant | Type | Domain | |---|---|---| | p.P123R (c.368C>G) | Missense | SH2 domain | | p.A9Pfs*76 (c.24delA) | Frameshift | 5′ KIR region | | p.M161Afs*46 (c.476_480dupGCCGC) | Frameshift | SOCS box | | p.R22W (c.64C>T) | Missense | 5′ KIR region | | p.Y154H (c.460T>C) | Missense | SH2 domain | | p.(Ala70Pro) (c.208G>C) | Missense | (functional domain, family with neurological phenotype) | | Chromosomal microdeletion (16p13.13) | Full-gene deletion | N/A |

All reported coding variants carry high CADD scores (>11.63), consistent with predicted deleteriousness (PMC7578789).

Functional consequence: Loss of function / haploinsufficiency. SOCS1 protein has three key functional domains: 1. A kinase inhibitory region (KIR) acting as a pseudosubstrate for JAK kinases 2. An SH2 domain that binds the JAK activation loop, directly inhibiting JAK catalytic activity 3. A SOCS box that recruits an Elongin B/C–Cullin5 E3 ubiquitin ligase complex, targeting bound substrates (including JAKs) for proteasomal degradation 4. A nuclear localization signal, enabling additional intranuclear regulatory roles (e.g., interaction with p53, modulation of NF-κB) (PMC11070515)

LOF variants disrupt one or more of these functions, producing reduced negative feedback on JAK1/JAK2/TYK2-STAT1/3/5/6 signaling downstream of type I/II interferons, IL-2, IL-4, IL-6, and leukemia inhibitory factor (LIF).

Origin: Germline, typically inherited in an autosomal dominant pattern with incomplete penetrance and variable expressivity; de novo occurrence has not been systematically characterized in the sources reviewed but is plausible given the pedigree data available.

Population frequency: gnomAD v4.0 pLI = 0.12; LOEUF = 1.47 (ENST00000332029) — indicating the gene is not under classical severe constraint against LOF variation in the general population, in apparent tension with (but not necessarily contradicting) its role in a highly penetrant-in-symptomatic-carriers monogenic disease, given incomplete penetrance (search result via genebe.net).

Epigenetic note (biologically related, distinct from the germline disease): SOCS1 promoter hypermethylation and transcriptional silencing is a well-documented somatic epigenetic event in several cancers (hepatocellular carcinoma, multiple myeloma), functioning as a tumor-suppressor-like mechanism distinct from germline haploinsufficiency (PMID:11326271; PMID:12456503) — relevant context for understanding SOCS1's dual role in cancer biology versus the germline immune dysregulation syndrome, though not itself part of the SOCS1-HI disease mechanism.

Modifier genes: None formally established; phenotypic discordance among carriers of identical variants strongly suggests unidentified genetic or epigenetic modifiers.

5. Environmental Information

  • Infectious triggers: SARS-CoV-2 is the most concretely documented environmental/infectious trigger, precipitating both cytopenia/enthesitis presentations and MIS-C-like multisystem inflammation in SOCS1+/- individuals (PubMed 32853638; Springer 2022; PMC11746893).
  • No specific toxin, occupational, or lifestyle risk factors have been reported for this rare monogenic condition in the literature surveyed.
  • Given the disease's cytokine-hypersensitivity mechanism, any acute inflammatory/infectious insult is mechanistically plausible as a trigger of clinical flares, though systematic study of this is limited to the COVID-19 examples above.

6. Mechanism / Pathophysiology

Core causal chain: Heterozygous SOCS1 LOF variant → reduced functional SOCS1 protein dosage → impaired negative feedback on JAK1/JAK2/TYK2 → exaggerated and prolonged STAT1 phosphorylation upon IFN-γ (and IFN-α/β) stimulation, comparable in magnitude to STAT1 gain-of-function disease → concurrently increased STAT5 phosphorylation (IL-2) and increased STAT6 phosphorylation (IL-4), with reduced STAT3 phosphorylation (IL-6) → downstream transcriptional dysregulation (upregulated CXCL9, CXCL10, CISH, PIM1) → cellular immune dysregulation (reduced Tregs, reduced Th17, expanded Th1 responses, monocyte/macrophage hyperactivation) → clinical autoimmunity, autoinflammation, and lymphoproliferation (PMC7578789; PMC8375263).

Molecular pathways (KEGG/Reactome-relevant): - JAK-STAT signaling pathway (KEGG hsa04630) — central pathway - Downstream PI3K-AKT-mTOR pathway component: loss of SOCS1 E3 ligase activity is associated with increased FAK1 and enhanced phosphorylated AKT and p70 ribosomal S6 kinase (RPS6K) in patient immune cells, indicating cross-talk beyond canonical JAK-STAT (PMC8375263) - NF-κB pathway modulation via nuclear SOCS1

Cellular processes: - Impaired regulatory T-cell (Treg) development/function: reduced CD4+CD25+FOXP3+ Tregs, lower FOXP3/HELIOS/CD25 expression, and moderately reduced suppressive activity — distinguishes SOCS1-HI from STAT1 gain-of-function disease, where Tregs are typically preserved (PMC7578789; PMC8375263) - Reduced Th17 cells (CD3+CD4+CXCR3-CCR6+) secondary to reduced STAT3 phosphorylation following IL-6 stimulation, phenocopying an aspect of STAT3 loss-of-function disease despite the opposite direction of the primary genetic lesion - Cytokine hypersensitivity of T and B lymphocytes to IFN-γ, IL-2, and IL-4 - B-cell abnormalities including hypogammaglobulinemia and B-cell maturation deficiency reported in a subset of patients - Monocyte/macrophage hyperinflammatory phenotype (relevant to the GLILD/granulomatous manifestations)

Protein dysfunction: Loss-of-function of SOCS1's SH2-domain JAK-binding, KIR pseudosubstrate inhibition, and/or SOCS-box-mediated E3 ubiquitin ligase activity, leading to failure of JAK degradation and prolonged kinase activity.

Immune system involvement: This is fundamentally an immune dysregulation disease — combining features of autoimmunity (SLE-like disease, cytopenias, organ-specific autoimmunity), autoinflammation (granulomatous disease, GLILD, enthesitis), and mild immunodeficiency (infection susceptibility, hypogammaglobulinemia in some), consistent with its classification among the ALPID (autoimmune lymphoproliferative immunodeficiency) spectrum of IEIs (PMC10499775).

Tissue damage mechanisms: In the intestinal phenotype, CD8+ T-lymphocyte infiltration of the muscularis (lymphocytic leiomyositis) drives obstructive GI symptoms; ruxolitinib treatment produced "significant decrease of the CD8+ T lymphocyte muscular infiltrate, and normalization of serum and intestinal cytokines" (PMC10354128). In neurological disease, reduced intraepidermal nerve fiber density suggests inflammatory small-fiber neuropathy; SOCS1 is proposed to "act as a regulator of the inflammatory response in perineural tissues, thus preventing nerve damage" when intact (PMC12628480).

Genotype-severity correlation: Complete heterozygous gene deletions may produce milder phenotypes than certain heterozygous C-terminal point variants, suggesting some missense/truncating alleles may act partly through dominant-negative mechanisms rather than pure dosage loss.

Suggested ontology terms: - GO:0004860 (protein kinase inhibitor activity, relevant to KIR function); GO:0007259 (JAK-STAT cascade); GO:0060333 (interferon-gamma-mediated signaling pathway); GO:0031398 (positive regulation of protein ubiquitination) - CL:0000815 (regulatory T cell); CL:0000899 (Th17 cell); CL:0000236 (B cell); CL:0000576 (monocyte) - Molecular function: ubiquitin-protein transferase activity (SOCS-box/Elongin BC/Cullin5 E3 ligase complex)

Molecular profiling data: No large-scale transcriptomic/proteomic/metabolomic dataset specific to SOCS1-HI was identified in the sources reviewed; most functional characterization derives from targeted phospho-flow cytometry (pSTAT1/3/5/6) and flow immunophenotyping of patient PBMCs rather than unbiased omics.

7. Anatomical Structures Affected

Organ level (primary): - Hematologic/lymphoid system — bone marrow (hypocellularity reported), spleen, lymph nodes (lymphoproliferation) - Skin — psoriasis, discoid lupus, atopic dermatitis - Joints/entheses — spondyloarthritis, severe enthesitis - Kidney — lupus glomerulonephritis - Liver — autoimmune hepatitis - Pancreas — autoimmune pancreatitis - Gastrointestinal tract — Crohn's-like disease, coeliac disease, intestinal pseudo-obstruction, lymphocytic leiomyositis of intestinal muscularis - Lung — GLILD, organizing pneumonia - Eye — granulomatous uveitis - Thyroid — autoimmune thyroiditis - Central and peripheral nervous system — MS (CNS demyelination), limbic encephalitis, small-fiber peripheral neuropathy (CRPS)

Body systems involved: Hematologic/immune, musculoskeletal, dermatologic, gastrointestinal, hepatic, endocrine, respiratory, ophthalmologic, nervous, renal — essentially multisystem.

Tissue/cell level: - Epithelial and connective tissue involvement in autoimmune organ disease - Smooth muscle (intestinal muscularis) infiltration by CD8+ T cells in the intestinal phenotype - Peripheral nerve fibers (reduced intraepidermal nerve fiber density) - Key immune cell populations: CD4+ T cells (Treg, Th1, Th17 subsets), CD8+ T cells, B cells, monocytes/macrophages

Suggested UBERON/CL terms: UBERON:0002370 (thymus), UBERON:0002371 (bone marrow), UBERON:0000178 (blood), UBERON:0001155 (colon), UBERON:0001987 (placenta N/A), UBERON:0000955 (brain), UBERON:0001021 (nerve); CL:0000815 (Treg), CL:0000899 (Th17), CL:0000625 (CD8+ T cell), CL:0000236 (B cell).

Subcellular level: Cytoplasmic JAK-STAT signaling complexes at the plasma membrane/cytoplasm (GO:0005737 cytoplasm); nuclear translocation of phosphorylated STATs and of SOCS1 itself via its nuclear localization signal (GO:0005634 nucleus).

Laterality: Not applicable/not systematically reported (systemic, bilateral/multisystem disease).

8. Temporal Development

Onset: - Median age of onset: 7.5 years (range 2–44 years) across the founding cohort; several patients present in early childhood (as young as 2 years) with cytopenia or enthesitis, while others (e.g., MS, adult SLE) present in adulthood up to age 44 (PMC7578789) - Onset pattern is variable — can be acute (e.g., infection-triggered thrombocytopenia) or insidious (e.g., slowly progressive organ-specific autoimmunity)

Progression: - No formal staging system exists for this condition. - Disease course is highly variable: some patients have a single self-limited autoimmune episode (e.g., transient ITP), others develop chronic, relapsing, or progressive multi-organ disease (e.g., relapsing-remitting MS, recurrent CRPS episodes — 8 debilitating episodes documented in one patient, refractory thrombocytopenia) - Lymphoproliferation can be chronic/benign or evolve into malignancy (one Hodgkin lymphoma case at age 34, following prior chronic lymphoproliferation)

Patterns: - Remission: Some cytopenias remit spontaneously or with treatment; JAK inhibitor therapy has induced sustained clinical and laboratory remission in several reported cases. - Critical periods: Acute infection appears to represent a critical "unmasking" window in which previously asymptomatic carriers develop overt disease (documented for SARS-CoV-2). - Asymptomatic carrier state: ~33% of genetically confirmed carriers remain clinically silent, sometimes for decades (asymptomatic carriers reported aged 10–62 years), indicating the disease can remain latent indefinitely in some individuals.

9. Inheritance and Population

Epidemiology: - SOCS1-HI is an ultra-rare disease. As of the most recent systematic review (Sept 2024), the entire published literature comprised 9 publications describing 33 patients (Lancet Rheumatology 2024); an earlier estimate cited "over 10 families" reported since 2020 (PMC11070515). No formal population prevalence or incidence estimate (cases per 100,000) exists; the condition is considered likely underdiagnosed, given its recent description (2020) and pleiotropic, easily-misattributed clinical presentations.

Inheritance pattern: Autosomal dominant with incomplete penetrance and variable expressivity.

Penetrance: - Incomplete — approximately ~67% of genetically confirmed carriers are symptomatic (5/15 asymptomatic in the founding cohort); the Lancet Rheumatology 2024 registry study confirms penetrance is incomplete and higher in females than males.

Expressivity: Markedly variable, even within families carrying an identical variant — ranging from asymptomatic status to severe multi-organ disease (e.g., the multi-generational family with the p.(Ala70Pro) variant showing a spectrum from CRPS/encephalitis in a child to adult-onset MS in the father).

Genetic anticipation: Not reported/established in the literature reviewed.

Germline mosaicism: Not specifically reported.

Founder effects: Not established; variants identified to date appear to be distinct across unrelated families (no recurrent founder allele described in the sources reviewed).

Consanguinity: Not implicated — this is a dominant, not recessive, disease mechanism.

Carrier frequency: Not established in general population screening databases; gnomAD constraint metrics (pLI 0.12) suggest rare LOF variants in SOCS1 do occur in the general population without necessarily causing recognized disease, consistent with incomplete penetrance.

Population demographics: - Sex ratio: Female predominance in autoimmune manifestation expression (though the genetic variant itself is autosomal, not sex-linked) — mirrors the female bias seen in SLE and confirmed in heterozygous SOCS1+/- mouse models. - Geographic/ethnic distribution: No specific ethnic or geographic clustering has been reported; cases have been described across European and US cohorts (reflecting the ESID-affiliated European SOCS1 study group and a parallel US SOCS1 study group). - Age distribution: Spans pediatric to late adulthood (documented cases from age 2 to 62).

10. Diagnostics

No formal consensus diagnostic criteria exist for SOCS1-HI given its recent characterization (2020) and rarity. Diagnosis is established through a combination of:

Genetic testing: - Targeted gene sequencing / IEI gene panels including SOCS1 — the primary diagnostic modality - Whole exome sequencing (WES) — used in essentially all reported index cases to identify the causal variant, often in the context of a broader IEI/autoimmunity gene panel workup - Chromosomal microarray (CMA) — relevant for detecting 16p13.13 microdeletions encompassing SOCS1 (as in the pediatric enthesitis/thrombocytopenia case) - Variant interpretation follows standard ACMG/AMP guidelines; functional/in vitro validation (phospho-flow STAT assays) is recommended to support pathogenicity given the gene's relative population tolerance (pLI 0.12) and to distinguish disease-causing from benign heterozygous variants

Functional/immunological studies (supportive, not yet standardized as formal diagnostic criteria): - Phospho-flow cytometry measuring STAT1, STAT5, STAT6 phosphorylation in response to IFN-γ, IL-2, IL-4 stimulation (elevated/prolonged in patients) and STAT3 phosphorylation in response to IL-6 (reduced) - Flow immunophenotyping: reduced Treg frequency/function, reduced Th17 cells - Elevated STAT-responsive gene transcripts (CXCL9, CXCL10, CISH, PIM1) - Ex vivo ruxolitinib "correction" assays — demonstrating that JAK inhibition normalizes the hyperphosphorylation phenotype, both supporting diagnosis and predicting therapeutic response

Laboratory/clinical tests supporting individual manifestations: - CBC with differential (cytopenias), Coombs test (AIHA), anti-DNA/ANA/anti-GAD antibodies (autoimmunity workup), immunoglobulin levels (hypogammaglobulinemia in some), bone marrow biopsy (hypocellularity), skin/lung/GI biopsy with histopathology (e.g., CD8+ lymphocytic leiomyositis on intestinal biopsy, granulomatous change in GLILD) - Imaging: MRI (enthesitis, CNS demyelination in MS/encephalitis), radiologic assessment of joints

Differential diagnosis: STAT1 gain-of-function disease (shares STAT1 hyperactivation but typically preserves Tregs, unlike SOCS1-HI); STAT3 loss-of-function disease (shares reduced Th17/STAT3 signaling); other ALPS-like/ALPID conditions; primary SLE; idiopathic ITP/AIHA when presenting in isolation without recognized syndromic features.

Screening: No established population or newborn screening program exists (disease too rare/recently characterized); cascade genetic testing of relatives of an index case (as performed in the reported families) is the practical equivalent of targeted "screening" currently used.

11. Outcome/Prognosis

  • No formal survival statistics (5-year/10-year survival), life-expectancy data, or population mortality rate have been established for this ultra-rare, recently described condition.
  • Disease course is highly variable — from asymptomatic lifelong carriage to severe treatment-refractory multi-organ autoimmune/autoinflammatory disease.
  • Malignancy risk: at least one documented progression from chronic lymphoproliferation to Hodgkin lymphoma (age 34), suggesting a potential (not yet quantified) elevated lymphoma risk analogous to other ALPS-spectrum disorders.
  • Complications: bone marrow hypocellularity/refractory thrombocytopenia, glomerulonephritis (lupus nephritis), intestinal obstruction (lymphocytic leiomyositis), CNS demyelination/seizures, debilitating recurrent CRPS pain episodes, hypogammaglobulinemia with associated infection risk.
  • Prognostic factors: Female sex is associated with higher penetrance and more frequent autoimmune manifestation; specific variant type/location (missense in functional domains vs. complete deletion) may correlate with severity, though this is based on limited case numbers rather than a validated prognostic model.
  • Treatment-modifying prognosis: JAK inhibitor therapy has produced meaningful clinical and immunological remission in multiple reported cases (normalized cytokine profiles, resolved obstructive GI symptoms, reduced autoantibody titers, improved cytopenia), suggesting that with recognition and targeted treatment, disease course can be substantially favorably altered — though long-term outcome data with JAK inhibition are not yet mature given the recency of the disease's description.

12. Treatment

Pharmacotherapy — JAK inhibitors (primary targeted therapeutic strategy): - Ruxolitinib (JAK1/JAK2 inhibitor) — demonstrated in vitro reduction of IFN-γ-induced STAT1 phosphorylation and IL-2-induced STAT5 phosphorylation, and suppression of IL-2-driven T-cell proliferation without affecting TCR-mediated responses (PMC7578789); clinically, ruxolitinib induced "rapid resolution of ... obstructive symptoms, significant decrease of the CD8+ T lymphocyte muscular infiltrate, and normalization of serum and intestinal cytokines" in a patient with lymphocytic leiomyositis (PMC10354128) - Baricitinib (JAK1/JAK2 inhibitor) — used in an SLE-phenotype patient (patient E1), starting at 2 mg once daily and escalated to 2 mg twice daily; produced decreased anti-DNA autoantibodies at 3 months and dose-correlated reduction in monocyte STAT1 phosphorylation (PMC7578789) - Tofacitinib (pan-JAK inhibitor) — used successfully in a pediatric patient with severe enthesitis, bone marrow hypocellularity, and refractory thrombocytopenia, with "excellent clinical and functional laboratory response" (Springer 2022) - Suggested NCIT term: NCIT:C15986 (Pharmacotherapy); therapeutic agent CHEBI terms: ruxolitinib CHEBI:71196; baricitinib CHEBI:90932; tofacitinib CHEBI:75236

Targeted cytokine blockade: - Emapalumab (anti-IFN-γ monoclonal antibody) — proposed/discussed as a promising option for highly IFN-γ-driven disease presentations, consistent with mouse-model data showing that anti-IFN-γ antibody administration rescues the lethal SOCS1-/- phenotype (Cell, PMID:10490099; PMC11070515) - IL-4Rα blockade (e.g., dupilumab-class mechanism) and IL-17A blockade — shown in murine SOCS1 haploinsufficiency models to rescue autoinflammation, supporting these as candidate targeted biologic strategies (PMID:38157076, "IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency")

Experimental/emerging: - SOCS1-mimetic peptides — small peptides designed to replicate SOCS1's KIR pseudosubstrate function; still experimental, limited by "high costs, low permeability, difficulties of intracellular delivery, proteolytic instability" (PMC11070515) - Hematopoietic stem cell transplantation (HSCT) and gene therapy — proposed as potentially curative approaches by analogy to other severe monogenic IEIs, but not yet applied in reported SOCS1-HI patients

Supportive/organ-specific care: - Standard immunosuppressive/anti-inflammatory agents for individual manifestations prior to/alongside JAK inhibition (e.g., corticosteroids, conventional cytopenia management) — used in earlier case reports before the JAK-inhibitor mechanism was recognized

Treatment strategy: Given the mechanistic homogeneity (JAK/STAT hyperactivation) underlying phenotypically diverse presentations, JAK inhibition represents a rational, mechanism-based, "precision medicine" approach applicable across the phenotypic spectrum (autoimmune, autoinflammatory, and lymphoproliferative manifestations alike), representing a genotype-informed treatment algorithm rather than organ-by-organ symptomatic management.

Adverse events: Not systematically reported for this population; general JAK-inhibitor class safety profile (infection risk, cytopenia, thrombosis risk) would be expected to apply, warranting caution given baseline cytopenia risk in this population.

13. Prevention

No disease-specific primary, secondary, or tertiary prevention programs, immunization strategies, or population screening programs exist for this ultra-rare, recently described monogenic condition.

  • Secondary prevention (practical, in current use): Cascade genetic testing of first-degree relatives of an identified proband, enabling early recognition of asymptomatic/pre-symptomatic carriers who could be monitored for the onset of autoimmune/autoinflammatory manifestations, and potentially treated pre-emptively or promptly upon symptom onset.
  • Genetic counseling: Recommended given autosomal dominant inheritance with ~50% transmission risk to offspring, tempered by counseling regarding incomplete penetrance (documented asymptomatic carriers into the 6th decade of life) and variable expressivity.
  • Infection-avoidance counseling: Given the documented role of infection (notably SARS-CoV-2) as a disease-unmasking trigger, heightened vigilance for new autoimmune/autoinflammatory symptoms following acute infections in known carriers is a reasonable, though not formally validated, clinical practice.
  • Prophylaxis: No specific prophylactic medication regimen has been established or studied.

14. Other Species / Natural Disease

  • Naturally occurring SOCS1 haploinsufficiency in non-human species has not been reported in the literature surveyed. The primary cross-species data come from engineered mouse models (below) rather than spontaneous veterinary disease.
  • No OMIA (Online Mendelian Inheritance in Animals) entries or veterinary case series for spontaneous Socs1 haploinsufficiency were identified.
  • Comparative biology / evolutionary conservation: The SOCS gene family (SOCS1–SOCS7, CISH) is evolutionarily conserved across vertebrates, with core JAK-inhibitory domain architecture maintained; a phylogenetic study of SOCS gene family evolution across vertebrates exists (Mol Biol Evol 2019, academic.oup.com/mbe), underscoring deep conservation of this negative-feedback mechanism.
  • Mouse ortholog: Socs1, MGI:1354910 (MGI SOCS1).

15. Model Organisms

Complete SOCS1 knockout mice (Socs1-/-): - Foundational studies: Naka et al. 1998, Starr et al. 1998; Alexander et al. 1999 (Cell 98:597–608, PMID:10490099) and Marine et al. 1999 (Cell 98:609–616, PMID:10490100) - Phenotype: perinatal lethality (~3 weeks after birth) due to fulminant IFN-γ-driven multi-organ inflammation — monocytic infiltration of organs, fatty liver degeneration, thymic atrophy, progressive loss of B-lymphocyte maturation, and elevated baseline IFN-γ - Rescue experiments were mechanistically definitive: lethality was prevented by anti-IFN-γ neutralizing antibody administration and did not occur in Socs1-/-Ifng-/- double knockouts, directly establishing IFN-γ as the principal lethal mediator (Cell PMID:10490099) - Also rescued by concomitant Rag2 knockout (removing lymphocytes), demonstrating the fatal inflammatory phenotype is lymphocyte-dependent (Cell PMID:10490100)

Heterozygous mice (Socs1+/-) — the closer model of human haploinsufficiency: - Normal at birth - Develop progressive autoimmune manifestations with age: anti-dsDNA autoantibodies, inflammatory infiltration of lungs, salivary glands, and kidneys - Show female-predominant disease severity, closely mirroring the human female bias in SLE-like manifestations - Exhibit reduced Treg function - This heterozygous model provided the foundational prediction — years before human cases were identified — that partial SOCS1 loss would produce a lupus-like autoimmune phenotype, later confirmed by the 2020 human genetic discovery (PMC11070515)

Combined SOCS1/SOCS3 hematopoietic-specific knockouts: Show rapid, accelerated inflammation, further underscoring the non-redundant, critical negative-feedback role of this gene family in hematopoietic cells (PLOS ONE, journals.plos.org/plosone/article?id=10.1371/journal.pone.0162111).

Model applications: These mouse models have been used to (1) establish IFN-γ as the central pathogenic cytokine, informing the rationale for emapalumab as a candidate therapy; (2) demonstrate the JAK/STAT hyperactivation mechanism that underlies the rationale for JAK inhibitor therapy; and (3) test candidate biologic therapies — IL-4Rα and IL-17A blockade rescued autoinflammation in the Socs1 haploinsufficient mouse model (PMID:38157076), directly nominating these as translational therapeutic candidates for human SOCS1-HI.

Model limitations: The complete knockout is not a faithful haploinsufficiency model (it is uniformly lethal and represents complete rather than partial loss); the heterozygous mouse, while a better dosage match, does not fully recapitulate the extreme phenotypic breadth seen in humans (e.g., neurological manifestations such as MS/CRPS have not been reported as a feature of the mouse heterozygous model in the sources reviewed), and no mouse model to date has reproduced the lymphoproliferative-to-lymphoma progression seen in at least one human patient.

Resources: MGI:1354910 (Socs1 mouse gene record, informatics.jax.org).

Summary of Key Evidence Gaps

  • No formal population prevalence/incidence estimate exists (disease too rare/recently described)
  • No dedicated GeneReviews chapter or standardized diagnostic criteria identified
  • No large omics dataset (transcriptomic/proteomic) specific to patient cohorts identified
  • ClinGen Dosage Sensitivity curation for SOCS1 is not yet completed
  • Long-term outcome data on JAK-inhibitor-treated patients are not yet mature
  • Quality-of-life instrument data (EQ-5D/SF-36 or disease-specific) are absent from the literature reviewed

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 17
Resolved 16
Unresolved (possible confabulation) 1
Unverifiable 0
Quoted claims checked 2
Quoted claims found in source 1
Quoted claims not found in source 1
Quoted claims with nothing to check against 1
References weighed for topical relevance 16
On topic 11
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.1371/journal.pone.0162111](https://journals.plos.org (1 mention) - Identifier did not resolve to a record

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

  • PMC:PMC11070515 (abstract only): "high costs, low permeability, difficulties of intracellular delivery, proteolytic instability"
  • Text part not found as substring: 'high costs, low permeability, difficulties of intracellular delivery, proteolytic instability' (note: only abstract available for PMID:38711523, full text may contain this excerpt)

Quotes that could not be checked

There was no text to compare these against, so they are neither confirmed nor contradicted:

  • DOI:10.1007/s10875-022-01346-x: "excellent clinical and functional laboratory response"
  • Reference resolved but exposes no abstract or full text to search